# EDGAR Filing Document

**Accession Number:** 0001840748
**File Stem:** 0001558370-23-003531
**Filing Date:** 2023-3
**Character Count:** 6799
**Document Hash:** 18c90d173457adf121b7a4bb1d071b9b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-23-003531.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001558370-23-003531

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** LAVA Therapeutics NV
- **CENTRAL INDEX KEY:** 0001840748
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40241
- **FILM NUMBER:** 23725663

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM
- **BUSINESS PHONE:** 31 6 3000 3035

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** UTRECHT
- **STATE:** P7
- **ZIP:** 3584 CM

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LAVA Therapeutics BV
- **DATE OF NAME CHANGE:** 20210115

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 6-K**

------

**REPORT OF FOREIGN ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2023**

**(Commission File No. 001-40241)**

------

**LAVA Therapeutics N.V.**

**(Translation of registrant's name into English)**

------

**Yalelaan 60**

**3584 CM Utrecht, The Netherlands**

**(Address of principal executive offices)**

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

&nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☐

------

**LAVA Therapeutics, N.V.**

Effective March 9, 2023, LAVA Therapeutics, N.V. appointed Christy J. Oliger to its board of directors. Additionally, Stefan Luzi, M.Sc., M.Phil., Ph.D. stepped down from his role on the board of directors effective March 9, 2023.

On March 9, 2023, the Company issued a press release related to the foregoing matters. A copy of this press release is filed herewith as Exhibit 99.1.

#### EXHIBIT LIST

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [Press Release, dated March 13, 2023](tmb-20230313xex99d1.htm) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
|  | LAVA Therapeutics, N.V. | LAVA Therapeutics, N.V. |
|  | (Registrant) | (Registrant) |
| Date: March 13, 2023 | By: | /s/ Fred Powell |
|  | Fred Powell | Fred Powell |
|  | Chief Financial Officer  | Chief Financial Officer  |

---

------

## Exhibit 99.1

![Graphic](tmb-20230313xex99d1001.jpg)

**Exhibit 99.1**

**LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors**

**Utrecht, The Netherlands and Philadelphia, Pa., USA – February XX, 2023 –** LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board.

"As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three decades of strategic, operational and commercial leadership to the LAVA board," said Stephen Hurly, president and chief executive officer of LAVA Therapeutics. "We look forward to her guidance and expertise as we advance our pipeline of bispecific gamma-delta T cell engagers."

"On behalf of our board of directors and management team, I would like to thank Stefan for his years of service and the many valuable contributions he has made to LAVA," added Hurly. "We are grateful for his thoughtful guidance in key moments of the company's development and dedicated support over the years."

Christy J. Oliger has over 30 years of experience in the biopharmaceutical industry and is recognized for building highly effective teams, leading significant product launches and having broad therapeutic expertise. Most recently, Ms. Oliger served as senior vice president, Oncology Business Unit Head at Genentech, where she also held numerous senior leadership roles of increasing responsibility across a variety of therapeutic areas including oncology, neurology, rare disease, respiratory, dermatology and immunology. In addition, she led Roche's global portfolio management function comprised of a late-stage development portfolio of greater than 300 projects. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. She currently serves as a member of the board at Karyopharm Therapeutics, Reata Pharmaceuticals, and Replimune Therapeutics. She was a member of the board of Sierra Oncology until the company was acquired by GSK in 2022. Ms. Oliger holds a Bachelor of Arts in Economics from the University of California at Santa Barbara.

**About LAVA Therapeutics**

LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2)

------

![Graphic](tmb-20230313xex99d1001.jpg)

T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company's lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

**CONTACTS**

Investor Relations

ir@lavatherapeutics.com

Argot Partners (IR/Media)

212-600-1902<br>lava@argotpartners.com

------